Literature DB >> 28641533

Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis.

Mariana Pehar1, Benjamin A Harlan1, Kelby M Killoy1, Marcelo R Vargas1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of motor neurons in the spinal cord, brain stem, and motor cortex. The molecular mechanism underlying the progressive degeneration of motor neuron remains uncertain but involves a non-cell autonomous process. In acute injury or degenerative diseases astrocytes adopt a reactive phenotype known as astrogliosis. Astrogliosis is a complex remodeling of astrocyte biology and most likely represents a continuum of potential phenotypes that affect neuronal function and survival in an injury-specific manner. In ALS patients, reactive astrocytes surround both upper and lower degenerating motor neurons and play a key role in the pathology. It has become clear that astrocytes play a major role in ALS pathology. Through loss of normal function or acquired new characteristics, astrocytes are able to influence motor neuron fate and the progression of the disease. The use of different cell culture models indicates that ALS-astrocytes are able to induce motor neuron death by secreting a soluble factor(s). Here, we discuss several pathogenic mechanisms that have been proposed to explain astrocyte-mediated motor neuron death in ALS. In addition, examples of strategies that revert astrocyte-mediated motor neuron toxicity are reviewed to illustrate the therapeutic potential of astrocytes in ALS. Due to the central role played by astrocytes in ALS pathology, therapies aimed at modulating astrocyte biology may contribute to the development of integral therapeutic approaches to halt ALS progression. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Astrocytes; amyotrophic lateral sclerosis; gliosis; motor neuron; neurodegeneration; oxidative stress

Mesh:

Year:  2017        PMID: 28641533      PMCID: PMC5740017          DOI: 10.2174/1381612823666170622095802

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  218 in total

1.  Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system.

Authors:  D von Schack; E Casademunt; R Schweigreiter; M Meyer; M Bibel; G Dechant
Journal:  Nat Neurosci       Date:  2001-10       Impact factor: 24.884

Review 2.  Neuroglia: the 150 years after.

Authors:  Helmut Kettenmann; Alexei Verkhratsky
Journal:  Trends Neurosci       Date:  2008-10-20       Impact factor: 13.837

3.  Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation.

Authors:  Pablo Diaz-Amarilla; Ernesto Miquel; Andrés Trostchansky; Emiliano Trias; Ana M Ferreira; Bruce A Freeman; Patricia Cassina; Luis Barbeito; Marcelo R Vargas; Homero Rubbo
Journal:  Free Radic Biol Med       Date:  2016-03-22       Impact factor: 7.376

4.  Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis.

Authors:  G Almer; S Vukosavic; N Romero; S Przedborski
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

5.  The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.

Authors:  Savina Apolloni; Chiara Parisi; Maria Grazia Pesaresi; Simona Rossi; Maria Teresa Carrì; Mauro Cozzolino; Cinzia Volonté; Nadia D'Ambrosi
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

6.  TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

Authors:  Iga Wegorzewska; Shaughn Bell; Nigel J Cairns; Timothy M Miller; Robert H Baloh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-15       Impact factor: 11.205

7.  Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1.

Authors:  Marcelo R Vargas; Mariana Pehar; Pablo J Díaz-Amarilla; Joseph S Beckman; Luis Barbeito
Journal:  J Neurosci Res       Date:  2008-12       Impact factor: 4.164

8.  Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants.

Authors:  Patricia Cassina; Adriana Cassina; Mariana Pehar; Raquel Castellanos; Mandi Gandelman; Andrés de León; Kristine M Robinson; Ronald P Mason; Joseph S Beckman; Luis Barbeito; Rafael Radi
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

9.  Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis.

Authors:  D Nagy; T Kato; P D Kushner
Journal:  J Neurosci Res       Date:  1994-06-15       Impact factor: 4.164

10.  The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice.

Authors:  Megumi Akamatsu; Takenari Yamashita; Naoki Hirose; Sayaka Teramoto; Shin Kwak
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

View more
  29 in total

1.  Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1.

Authors:  Benjamin A Harlan; Mariana Pehar; Kelby M Killoy; Marcelo R Vargas
Journal:  FASEB J       Date:  2019-03-06       Impact factor: 5.191

2.  Identification of association fibers using ex vivo diffusion tractography in Alexander disease brains.

Authors:  Tadashi Shiohama; Natalie Stewart; Masahito Nangaku; Andre J W van der Kouwe; Emi Takahashi
Journal:  J Neuroimaging       Date:  2022-08-19       Impact factor: 2.324

Review 3.  Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.

Authors:  Alexander Starr; Rita Sattler
Journal:  Brain Res       Date:  2018-02-14       Impact factor: 3.252

4.  FABP7 upregulation induces a neurotoxic phenotype in astrocytes.

Authors:  Kelby M Killoy; Benjamin A Harlan; Mariana Pehar; Marcelo R Vargas
Journal:  Glia       Date:  2020-07-03       Impact factor: 7.452

Review 5.  Modification of Glial Cell Activation through Dendritic Cell Vaccination: Promises for Treatment of Neurodegenerative Diseases.

Authors:  Mohammadmahdi Sabahi; Asef Joshaghanian; Mahsa Dolatshahi; Parnian Jabbari; Farzaneh Rahmani; Nima Rezaei
Journal:  J Mol Neurosci       Date:  2021-03-13       Impact factor: 3.444

Review 6.  Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers.

Authors:  Björn F Vahsen; Elizabeth Gray; Alexander G Thompson; Olaf Ansorge; Daniel C Anthony; Sally A Cowley; Kevin Talbot; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2021-04-29       Impact factor: 42.937

7.  Recovery of Depleted miR-146a in ALS Cortical Astrocytes Reverts Cell Aberrancies and Prevents Paracrine Pathogenicity on Microglia and Motor Neurons.

Authors:  Marta Barbosa; Cátia Gomes; Catarina Sequeira; Joana Gonçalves-Ribeiro; Carolina Campos Pina; Luís A Carvalho; Rui Moreira; Sandra H Vaz; Ana Rita Vaz; Dora Brites
Journal:  Front Cell Dev Biol       Date:  2021-04-23

Review 8.  Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia.

Authors:  Katrina Albert; Jonna Niskanen; Sara Kälvälä; Šárka Lehtonen
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 9.  DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity.

Authors:  Jannigje Rachel Kok; Nelma M Palminha; Cleide Dos Santos Souza; Sherif F El-Khamisy; Laura Ferraiuolo
Journal:  Cell Mol Life Sci       Date:  2021-06-26       Impact factor: 9.261

Review 10.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.